Genfit set to raise $100m in Nasdaq IPO
French Genfit SA has registered at SEC for an Nasdaq IPO of ADS in conjunction with private placements in Europe and the US.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1118 entries already.
Entries by Thomas Gabrielczyk
Targeting NFkappaB protects tendons from injury
/in News/by Thomas GabrielczykResearchers from the UK and the US have prevented tendon injury and degeneration by simply blocking a key signalling pathway in inflammation.
Anaveon bags CHF35m series A financing
/in News/by Thomas GabrielczykUniversity Zurich spin-off Anaveon AG announced it will proceeds from its financing round to push development of its preclinical IL-2-receptor agonist.
AMR network CARB-X expands reach
/in News/by Thomas GabrielczykThe global antibacterial innovation network CARB-X has expanded its reach by adding six new life-science organisations to its fight against antimicrobial resistance (AMR).
Roche swallows Spark Therapeutics in $4.3bn deal
/in News/by Thomas GabrielczykSwiss pharma giant Roche has complemented its drug pipeline in the lucrative hemophilia A market by taking over hemophilia A gene therapy developer Spark Therapeutics for US$4.3bn.
How salt triggers allergy
/in News/by Thomas GabrielczykSodium chloride can promote immune responses that have been linked to atopic dermatitis. Researchers have now unraveled the mechanistic details between salt intake and activation of T cells.
Calypso Biotech cash in 20M Series A financing
/in News/by Thomas GabrielczykDutch autoimmunity specialist Calypso Biotech BV has raised 20m in a Series A financing co-led by Gilde Healthcare and Inkef Capital and co-financed by Johnson & Johnson Innovation – JJDC, Inc. (JJDC), and […]
Evotec and HZI join forces in antibiotics discovery
/in News/by Thomas GabrielczykEvotec AG and the Helmholtz Centre for Infection Research (HZI) have joined platforms in order to find novel resistance-breaking antibiotics against Gram-negative bugs.
First immunotolerant allogenic cell transplants revealed
/in News/by Thomas GabrielczykResearchers for the first time have found a way to prevent immune rejection of allogenic iPSC-derived cell and tissue transplants.
Arvelle Therapeutics raises $180m in Series A financing
/in News/by Thomas GabrielczykSwiss newco Arvelle Therapeutics has baged a $180m (159.1m) series A financing led by LSP. The company licenced the anti-epileptic candidate cenobamate (YKP3089) for $100m (88.4m) upfront from SK Biopharmaceuticals.